Iron Game
Veteran
SARMS represent an exciting new frontier in muscle building. When added to current favorites, MC's IGF-1 Lr3 and testosterone. Lets compare each of the following, Mk-2866, gw-501516, anadarine S4, Ligandrol lvd 4033 . Selective Androgen receptor modulators listed below for review before purchase buy
GW501516 (Cardarine or GSK-516) acts as a PPARd modulator. It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and has been demonstrated to reverse metabolic abnormalities in obese subjects with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies
*
Ostarine is a selective androgen receptor modulator developed by GTx Inc for treatment of conditions like muscle wasting and osteoporosis. It is an orally active, potent and selective agonist for androgen receptors shown in animal and human studies to have anabolic effects in both muscle and bone. It has an androgenic potency around 1/3rd of its anabolic potency. It was shown in vitro to increase the ratio of osteoblast formation from bone marrow osteoprogenitor cells, and reduced the number of new osteoclasts formed. It produced dose-dependent increases in bone mineral density and mechanical strength in vivo, as well as decreasing body fat and increasing lean body mass.
*
Andarine is an orally active agonist for androgen receptors. In an animal model of benign prostatic hypertrophy, Andarine was shown to reduce prostate weight with similar efficacy to Finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. This suggests that it is able to block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic therapies traditionally used for treatment of BPH. Studies showed that it is rapidly absorbed and highly bioavailable after oral doses capable of maximal pharmacologic activity. The favorable pharmacokinetics of Andarine permits convenient low doses and show that it is a strong candidate for continued clinical development.
*
LGD-4033 is a selective androgen receptor modulator. It is a non-steroidal SARM that binds to AR with high affinity (Ki of ~1 nM), developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. Expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands.
SARMS represent an exciting new frontier in muscle building. When added to current favorites, MC's IGF-1 and testosterone
GW501516 (Cardarine or GSK-516) acts as a PPARd modulator. It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and has been demonstrated to reverse metabolic abnormalities in obese subjects with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies
*
Ostarine is a selective androgen receptor modulator developed by GTx Inc for treatment of conditions like muscle wasting and osteoporosis. It is an orally active, potent and selective agonist for androgen receptors shown in animal and human studies to have anabolic effects in both muscle and bone. It has an androgenic potency around 1/3rd of its anabolic potency. It was shown in vitro to increase the ratio of osteoblast formation from bone marrow osteoprogenitor cells, and reduced the number of new osteoclasts formed. It produced dose-dependent increases in bone mineral density and mechanical strength in vivo, as well as decreasing body fat and increasing lean body mass.
*
Andarine is an orally active agonist for androgen receptors. In an animal model of benign prostatic hypertrophy, Andarine was shown to reduce prostate weight with similar efficacy to Finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. This suggests that it is able to block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic therapies traditionally used for treatment of BPH. Studies showed that it is rapidly absorbed and highly bioavailable after oral doses capable of maximal pharmacologic activity. The favorable pharmacokinetics of Andarine permits convenient low doses and show that it is a strong candidate for continued clinical development.
*
LGD-4033 is a selective androgen receptor modulator. It is a non-steroidal SARM that binds to AR with high affinity (Ki of ~1 nM), developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. Expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands.
SARMS represent an exciting new frontier in muscle building. When added to current favorites, MC's IGF-1 and testosterone
Last edited by a moderator:
